scispace - formally typeset
S

Sigrun Thorsdottir

Researcher at Karolinska Institutet

Publications -  7
Citations -  59

Sigrun Thorsdottir is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Pneumolysin & Medicine. The author has an hindex of 2, co-authored 4 publications receiving 25 citations. Previous affiliations of Sigrun Thorsdottir include Karolinska University Hospital.

Papers
More filters
Journal ArticleDOI

The role of microglia in bacterial meningitis : inflammatory response, experimental models and new neuroprotective therapeutic strategies

TL;DR: An overview on how microglia respond to bacterial pathogens targeting the brain, how the interplay betweenmicroglia and bacteria can be studied experimentally, and possible ways to use gained knowledge to identify novel preventive and therapeutic strategies are provided.
Journal ArticleDOI

Receptor Blockade: A Novel Approach to Protect the Brain From Pneumococcal Invasion.

TL;DR: In this paper, the authors suggest that adjunct treatment with pIgR and PECAM-1 antibodies to antibiotics may prevent pneumococcal meningitis development and associated brain damages.
Journal ArticleDOI

Dysfunctional Glymphatic System with Disrupted Aquaporin 4 Expression Pattern on Astrocytes Causes Bacterial Product Accumulation in the CSF during Pneumococcal Meningitis

TL;DR: The results clearly showed that during pneumococcal meningitis, the glymphatic system does not function because of a detachment of the astrocytic end feet from the blood-brain barrier (BBB) vascular endothelium, which leads to misplacement of AQP4 with the consequent loss of the AQP 4 water channel's functionality.
Journal ArticleDOI

Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA

TL;DR: Pneumococcal membrane particles (MPs) evoke a serotype-independent cross-protection against IPD, dependent on the presence of the two conserved lipoproteins MalX and PrsA, and it is suggested that MPs can be used for pneumococcal vaccine development.